New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
For media outside of the US, the UK & Canada only
Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients
For media outside USA, UK and Canada only
Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions
Ex US & UK Medical Media Only
Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia
Boehringer Ingelheim pioneers biopharmaceuticals move to China
LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma
For non U.S. Media Only
Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study
